Circulatory Shock
7
2
3
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 15/100
0.0%
0 terminated out of 7 trials
100.0%
+13.4% vs benchmark
14%
1 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (7)
Capillary Refill Time Variation to Predict Oxygen Comsumption Variation After FLuid Challenge (CARTOFL)
Peripheral pULSe Assessment and Arterial pRessure (PULSAR)
Shock and Acute Conditions OutcOmes Platform
Physiologic Effect of Topical Nitroglycerin on Microcirculation Capacity in Patients With Circulatory Shock.
Efficacy of the Use of Vasopressin as a Primary Vasoconstrictor in Critically Ill Patients
The RIsk Stratification in COVID-19 Patients in the ICU Registry
Vasopressin or Norepinephrine in Vasoplegic Shock After Non-cardiac Surgery